(Q34457919)

English

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes (English)

1 reference

Europe PubMed Central

2 August 2017

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Anne L Peters

7

0 references

Apostolos Tsapas

object named as

Apostolos Tsapas

8

0 references

object named as

John B Buse

3

0 references

Eleuterio Ferrannini

5

object named as

Ele Ferrannini

1 reference

Europe PubMed Central

2 August 2017

Richard M Bergenstal

2

object named as

Richard M Bergenstal

1 reference

Europe PubMed Central

2 August 2017

Michaela Diamant

4

object named as

Michaela Diamant

1 reference

Europe PubMed Central

2 August 2017

Silvio E Inzucchi

1

object named as

Silvio E Inzucchi

1 reference

Europe PubMed Central

2 August 2017

author name string

Michael Nauck

6

1 reference

Europe PubMed Central

2 August 2017

Richard Wender

9

1 reference

Europe PubMed Central

2 August 2017

David R Matthews

10

1 reference

Europe PubMed Central

2 August 2017

publication date

13 January 2015

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

58

1 reference

Europe PubMed Central

2 August 2017

3

1 reference

Europe PubMed Central

2 August 2017

429-442

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1007/s00125-014-3460-0

0 references

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Pioglitazone use and the risk of bladder cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Pioglitazone and bladder cancer: a propensity score matched cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Use of metformin in the setting of mild-to-moderate renal insufficiency

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Review: metformin: potential benefits and use in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Unleash metformin: reconsideration of the contraindication in patients with renal impairment

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

A stepwise approach to insulin therapy in patients with type 2 diabetes mellitus and basal insulin treatment failure.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

U-500 regular insulin: clinical experience and pharmacokinetics in obese, severely insulin-resistant type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

High GADA titer increases the risk of insulin requirement in LADA patients: a 7-year follow-up (NIRAD study 7).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insuli

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3460-0

21 January 2018

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of canagliflozin on serum electrolytes in patients with type 2 diabetes in relation to estimated glomerular filtration rate (eGFR)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin: the safest hypoglycaemic agent in chronic kidney disease?

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/25583541

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-014-3460-0

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34457919&oldid=1991406952"